Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Julphar
Baxter
Moodys
QuintilesIMS
Boehringer Ingelheim
Teva
Deloitte
Chubb

Generated: May 23, 2018

DrugPatentWatch Database Preview

ANZEMET Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

When do Anzemet patents expire, and when can generic versions of Anzemet launch?

Anzemet is a drug marketed by Us Pharm Holdings and is included in two NDAs.

The generic ingredient in ANZEMET is dolasetron mesylate. There are four drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the dolasetron mesylate profile page.
Drug patent expirations by year for ANZEMET
Pharmacology for ANZEMET
Synonyms for ANZEMET
(2,6,8,9a)-octahydro-3-oxo-2,6-methano-2H-quinolizin-8-yl-1Hindole-3-carboxylate monomethanesulfonate, monohydrate
(2alpha,6alpha,8alpha,9abeta)-octahydro-3-oxo-2,6-methano-2h-quinolizin-8-yl-1h-indole-3-carboxylate
(2alpha,6alpha,8alpha,9abeta)-Octahydro-3-oxo-2,6-methano-2H-quinolizin-8-yl-1H-indole-3-carboxylate monomethanesulfonate
(2R,6R,8R,9aS)-3-oxooctahydro-2H-2,6-methanoquinolizin-8-yl 1H-indole-3-carboxylate
(3R)-10-oxo-8-azatricyclo[5.3.1.03,8]undec-5-yl 1H-indole-3-carboxylate
10-OXO-8-AZATRICYCLO[5.3.1.0(3),?]UNDECAN-5-YL 1H-INDOLE-3-CARBOXYLATE
115956-12-2
115956-13-3
1H-Indole-3-carboxylic acid [(9aS)-octahydro-3-oxo-2alpha,6alpha-methano-2H-quinolizin]-8alpha-yl ester
1H-Indole-3-carboxylic acid 10-oxo-8-aza-tricyclo[5.3.1.03,8]undec-5-yl ester
1H-indole-3-carboxylic acid-trans-octahydro-3-oxo-2,6-methano-2H-quinolizin-8-yl ester methanesulfonate
1H-Indole-3-carboxylic acid, octahydro-3-oxo-2,6-methano-2H-quinolizin-8-yl ester, (2alpha,6alpha,8alpha,9abeta)-
1H-Indole-3-carboxylic acid, octahydro-3-oxo-2,6-methano-2H-quinolizin-8-yl ester, (2alpha,6alpha,8alpha,9abeta)-, monomethanesulfonate
1H-Indole-3-carboxylic acid, octahydro-3-oxo-2,6-methano-2H-quinolizin-8-yl ester, stereoisomer
1H-Indole-3-carboxylicacid, octahydro-3-oxo-2,6-methano-2H-quinolizin-8-yl ester, stereoisomer
3-oxooctahydro-2h-2,6-methanoquinolizin-8-yl 1h-indole-3-carboxylate
3594AH
71YF100S3H
82WI2L7Q6E
878143-33-0
956D133
AB00698337-03
AC-8828
AC1L1FA2
AC1L1TNT
AC1MHWDD
AC1Q6P88
AC1Q6P89
ACMC-20cc5g
AJ-62451
AK104158
AKOS022184758
AKOS025402394
AKOS025404537
AKOS030526960
Anemet
Anzemet (TN)
Anzemet Cinv
Anzemet hydrate
API0002473
AS-13228
BDBM50451546
BIDD:GT0287
C07866
C19H20N2O3.CH4O3S
C19H20N2O3.CH4O3S.H2O
CCG-220885
CCG-222446
CHEBI:4682
CHEBI:94561
CHEMBL124754
CHEMBL2368924
CHEMBL2368925
CS-3746
CS-3747
CTK4A9574
D00YLW
D07867
Dalasetron (Mesylate hydrate)
Dalasetron Mesylate Hydrate
DB00757
dolasetron
Dolasetron (INN)
Dolasetron (Mesylate hydrate)
Dolasetron [INN:BAN]
Dolasetron mesilate
DOLASETRON MESYLATE
Dolasetron mesylate [USAN:USP]
Dolasetron mesylate [USAN]
Dolasetron mesylate hydrate
Dolasetron mesylate hydrate, >=98% (HPLC), powder
DOLASETRON MESYLATE MONOHYDRATE
Dolasetron methanesulfonate hydrate
Dolasetronum
Dolasetronum [INN-Latin]
Dolasteron
DR001463
DTXSID4048276
FT-0631080
FT-0631081
H668
HY-B0750
HY-B0750B
Indole-3-carboxylic acid, ester with (8R)-hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3(4H)-one, monomethanesulfonate
KB-50417
LS-172300
LS-82766
MDL 73,147EF
MDL 73147EF
MDL-73147EF
MolPort-023-220-279
NCGC00181048-01
octahydro-3-oxo-2,6-methano-2H-quinolizin-8-yl 1H-indole-3-carboxylate
PL035017
PL042427
Q-101000
QTFFGPOXNNGTGZ-LIFGOUTFSA-N
RT-012406
SCHEMBL1237588
SCHEMBL14014817
SCHEMBL1819898
SCHEMBL42063
SCHEMBL42064
SCHEMBL42065
SCHEMBL4450258
UKTAZPQNNNJVKR-KJGYPYNMSA-N
UKTAZPQNNNJVKR-PIGZVRMJSA-N
UKTAZPQNNNJVKR-UHFFFAOYSA-N
UNII-71YF100S3H
UNII-82WI2L7Q6E
UNII-82WI2L7Q6E component UKTAZPQNNNJVKR-MRFVTOPCSA-N
VA10755
ZINC100019093
ZINC100038399
ZINC103105084
ZINC2688

US Patents and Regulatory Information for ANZEMET

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Us Pharm Holdings ANZEMET dolasetron mesylate INJECTABLE;INJECTION 020624-002 Sep 11, 1997 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Us Pharm Holdings ANZEMET dolasetron mesylate TABLET;ORAL 020623-001 Sep 11, 1997 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Us Pharm Holdings ANZEMET dolasetron mesylate INJECTABLE;INJECTION 020624-001 Sep 11, 1997 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Us Pharm Holdings ANZEMET dolasetron mesylate INJECTABLE;INJECTION 020624-003 Dec 11, 2001 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Expired US Patents for ANZEMET

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Us Pharm Holdings ANZEMET dolasetron mesylate TABLET;ORAL 020623-002 Sep 11, 1997 ➤ Try a Free Trial ➤ Try a Free Trial
Us Pharm Holdings ANZEMET dolasetron mesylate INJECTABLE;INJECTION 020624-001 Sep 11, 1997 ➤ Try a Free Trial ➤ Try a Free Trial
Us Pharm Holdings ANZEMET dolasetron mesylate INJECTABLE;INJECTION 020624-002 Sep 11, 1997 ➤ Try a Free Trial ➤ Try a Free Trial
Us Pharm Holdings ANZEMET dolasetron mesylate TABLET;ORAL 020623-002 Sep 11, 1997 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
US Army
Mallinckrodt
Merck
Teva
Fuji
Chinese Patent Office
Accenture
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.